Francesco Celi, MD
Endocrinology, Diabetes & Metabolism · Farmington, CTNPI 1427320761
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $37,207 of the $48,165 with a category attached, or 77.3%. 9 manufacturers reported payments, led by Amneal Pharmaceuticals LLC at 27.9% of the total. Among endocrinology, diabetes & metabolism clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 31 payments — averaging $1553.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amneal Pharmaceuticals LLC$13K
- Xeris Pharmaceuticals, Inc.$12K
- Avion Pharmaceuticals$11K
- IBSA Pharma Inc.$5K
- Acella Pharmaceuticals, LLC$3K
- Amgen$2K
- plus $3K from 3 others
Across 3 payments — averaging $8294.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- IBSA Institut Biochimique SA$25K
What the payments were for
- Consulting fees$37,20777%
- Speaking & faculty fees$8,93419%
- Travel & lodging$1,0382%
- Food & beverage$9852%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amneal Pharmaceuticals LLC | 6 | $13,438 |
| Xeris Pharmaceuticals, Inc. | 4 | $12,073 |
| Avion Pharmaceuticals | 4 | $10,775 |
| IBSA Pharma Inc. | 10 | $4,656 |
| Acella Pharmaceuticals, LLC | 2 | $2,884 |
| Amgen | 1 | $1,800 |
| Novo Nordisk | 2 | $1,381 |
| Ascendis Pharma Endocrinology Inc | 1 | $1,131 |
| Novartis | 1 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RECORLEV$6,031
- Tirosint$4,503
- Tirosint-SOL$3,038
- NP Thyroid$2,680
- TEPEZZA$1,800
- NP Thyroid 60$204
How this compares
$48,165 in reported general payments places this provider in the 90th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
See all endocrinology, diabetes & metabolism providers in Connecticut →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 18 | $28,631 |
| TrulicityDulaglutide | 15 | $25,396 |
| LantusInsulin Glargine,hum.Rec.Anlog | 13 | $728 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 11 | $601 |
| Levothyroxine Sodium | 22 | $174 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,381 | $28,63118 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $13,438 | $17422 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
Other endocrinology, diabetes & metabolism in Farmington
- Egils BogdanovicsTorrington$608K
- Ania JastreboffNew Haven$536K
- Robert ObersteinHartford$516K
- Fadi Al-KhayerStorrs$489K
- Silvio InzucchiNew Haven$461K
- Philip GoldbergNew Haven$324K
- Kevan HeroldNew Haven$261K
- Joseph RosenblattNew Britain$235K
- David DomenichiniBloomfield$220K
- Glenn RichTrumbull$210K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.